BridgeBio Pharma, Inc. annual gross profit for fiscal 2025 was $481 million, an increase of 120.7% from $218 million in fiscal 2024. All figures are reported results from public filings — no estimates or projections.
| Gross Profit (annual) | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Gross Profit | $481M | $218M | $7M | $74M | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Gross Profit (quarterly) | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
|---|---|---|---|---|---|---|
| Gross Profit | $185M | $146M | $114M | $107M | $114M | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
More BBIO metrics: Revenue · Operating Income · Net Income · EPS · Free Cash Flow
All BBIO financial statements → Interactive BBIO charts →
About TickerBase · Data methodology & sources